ALLIANCE PHARMA PLC

Director's Dealing • Feb 14, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8887W

Alliance Pharma PLC

14 February 2017

For immediate release	14 February 2017

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

PDMR shareholding

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that Peter Butterfield, a director of the Company and its Deputy CEO has today exercised an option granted under an employee share scheme over 90,222 ordinary shares of 1p each in the Company at 33.25p per share, and immediately sold 61,846 of these shares on the London Stock Exchange at a price of 48.75p per share to fund the subscription price and associated dealing costs.

Following these linked transactions, Mr Butterfield has a beneficial interest in 28,376 shares in the Company and holds options over a further 4,349,803 shares granted under the Company's employee share schemes.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

ANNEX

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Peter Butterfield

2

Reason for the notification

a)

Position/status

Deputy Chief Executive Officer

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma plc

b)

LEI

n/a

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

1p ordinary shares

ISIN: GB0031030819

b)

Nature of the transaction

1.   Exercise of options

2.   Sale

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1)   33.25p 2)   48.75p	1)   90,222 2)   61,846

d)

Aggregated information

- Aggregated volume

- Price

Exercise of 90,222 options at an exercise price of 33.25p per share

Sale of 61,846 shares at a price of 48.75p per share

e)

Date of the transaction

14 February 2017

f)

Place of the transaction

London Stock Exchange, AIM

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBRGDDRDBBGRS